Prestige Consumer Healthcare (NYSE:PBH) Updates FY25 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) issued an update on its FY25 earnings guidance on Thursday morning. The company provided EPS guidance of $4.40 to $4.46 for the period, compared to the consensus EPS estimate of $4.42. The company issued revenue guidance of $1.125 billion to $1.140 billion, compared to the consensus revenue estimate of $1.13 billion. Prestige Consumer Healthcare also updated its FY 2025 guidance to 4.460-4.460 EPS.

Analysts Set New Price Targets

PBH has been the subject of a number of recent analyst reports. DA Davidson upped their price objective on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a "buy" rating in a research note on Wednesday, August 28th. Jefferies Financial Group restated a "hold" rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of "Moderate Buy" and a consensus target price of $94.20.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock traded up $2.43 on Thursday, hitting $80.07. 355,414 shares of the stock were exchanged, compared to its average volume of 247,570. The firm's 50 day moving average is $72.31 and its two-hundred day moving average is $69.71. Prestige Consumer Healthcare has a one year low of $56.61 and a one year high of $81.25. The firm has a market capitalization of $3.97 billion, a PE ratio of 18.93, a P/E/G ratio of 2.08 and a beta of 0.47. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm had revenue of $267.10 million during the quarter, compared to analyst estimates of $260.54 million. During the same quarter last year, the business earned $1.06 earnings per share. The company's quarterly revenue was down 4.4% on a year-over-year basis. Sell-side analysts expect that Prestige Consumer Healthcare will post 4.43 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.